Nurix Therapeutics, Inc. (NRIX) SEC Filings & Earnings Calls

Dependence on Roche collaboration

“Because bexobrutideg is our lead drug candidate, our future prospects depend substantially on the success of the Roche collaboration.” · word for word

Clinical trial failure risk

“The risk of failure for our current lead drug candidates remains high.” · word for word

Need for additional capital

“We will need substantial additional funding to support our continuing operations and pursue our long-term business plan.” · word for word

Manufacturing reliance on single source CMOs

“We rely on third-party contract manufacturing organizations (CMOs) for the manufacture of both drug substance and finished drug product for our drug candidates for preclinical and clinical testing and expect to continue to do so for any future clinical trials and commercialization.”

Discontinuation of NX-2127 may indicate pipeline prioritization risk.

“Nurix made the decision to discontinue further clinical development of NX-2127” · word for word

Collaboration subject to customary closing conditions including HSR clearance.

“The collaboration agreement is subject to customary closing conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.” · word for word

Cash burn and going concern risk

“The Company does not expect its existing cash, cash equivalents and marketable securities to be sufficient to fund the completion of its clinical trials through commercialization and will need substantial additional funding to support its continuing operations and pursue its long-term business plan.” · word for word

Collaboration revenue dependency

“Total revenue $ 9,043 $ 44,056 (79) %”

Revenue decline due to collaboration end; net loss widening; high cash burn rate.

“Revenue decreased from $18.5M to $6.3M; net loss increased from $56.4M to $87.2M.”

Clinical trial failure risk

“Our lead drug candidates, bexobrutideg (NX-5948), zelebrudomide (NX-2127) and NX-1607, are in the early stages of clinical development and their risk of failure is high.” · word for word

Need for additional capital

“We will need substantial additional funding to support our continuing operations and pursue our long-term business plan.” · word for word

Dependence on collaborations

“We expect to depend on collaborations with third parties for the research, development and commercialization of certain of the drug candidates we may develop.” · word for word

Manufacturing and supply chain risk

“We rely on third-party contract manufacturing organizations (CMOs) for the manufacture of both drug substance and finished drug product for our drug candidates for preclinical and clinical testing and expect to continue to do so for any future clinical trials and commercialization.” · word for word

Intellectual property risk

“If we are unable to obtain and maintain patent protection for our technology, our current drug candidates and any future drug candidates that we may develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors and other third parties could develop and commercialize technology and drug candidates similar or identical t” · word for word

Clinical trial failure risk

“whether Nurix will be able to advance its drug candidates, obtain regulatory approval of and ultimately commercialize its drug candidates” · word for word

Financing risk

“whether Nurix will be able to fund development activities and achieve development goals” · word for word

Competition risk

“other risks and uncertainties described under the heading 'Risk Factors' in Nurix's Annual Report on Form 10-K” · word for word

Significant potential dilution from ATM program.

“Up to $413.65M in shares may be sold; dilutive to existing shareholders.”

Clinical-stage biotech with no approved products; regulatory and commercial risks remain high.

“clinical-stage biopharmaceutical company” · word for word

Early-stage pipeline risk

“We are early in our development efforts. Our lead drug candidates... are in the early stages of clinical development.” · word for word

Funding dependency

“We will need substantial additional funding. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs.” · word for word

Clinical trial risk remains; Phase 2 enrollment and regulatory approval are uncertain.

“Phase 2 clinical trial of bexobrutideg (DAYBreak-CLL-201) currently enrolling globally” · word for word